⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nihon Medi-Physics Co., Ltd. (NMP) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nihon Medi-Physics (NMP) is a leading Japanese radiopharmaceutical company established in 1973. The company specializes in the research, development, manufacturing, and distribution of diagnostic and therapeutic radiopharmaceuticals used in molecular imaging procedures, including SPECT and PET, to detect and diagnose diseases in neurology, cardiology, and oncology.
As of March 31, 2025, NMP is a wholly-owned subsidiary of GE HealthCare Technologies Inc., following GE HealthCare's acquisition of the remaining 50% stake previously held by Sumitomo Chemical. NMP operates multiple manufacturing facilities in Japan and serves as a center of excellence for GE HealthCare's molecular imaging and radiopharmaceutical business in the Asian market.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$183M
Founded:1973
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Radiopharmaceuticals, Small molecule, Theranostics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:GE HealthCare Technologies Inc.
Acquired By:GE HealthCare Technologies Inc. (2025-03-01)
Subsidiaries:NMP Business Support Co., Ltd.
Key Partnerships:GE HealthCare (Parent), PeptiDream (Strategic alliance for peptide-based theranostics), Eisai Co., Ltd. (Collaboration for dementia diagnosis)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Kevin O'Neill - President
LINKS
Website:nmp.co.jp
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nihon Medi-Physics Co., Ltd. (NMP). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.